Global Biotech Hubs: The World’s Leading Life Science Clusters and How They Connect

What Makes a Biotech Hub

A biotech hub, or life science cluster, is a region where the ingredients of drug development sit close together: research universities and hospitals that produce new science, venture capital to fund start-ups, laboratory space, a deep pool of experienced scientists and managers, and large pharma companies that partner with and buy local biotechs. When those ingredients reach critical mass, the hub sustains itself: successful companies train the next generation of founders, and returns attract the next round of capital.

Rankings try to measure that density. GEN’s annual ranking of US biopharma clusters, the most widely cited, scores regions on five indicators: NIH research funding, venture capital, patents, lab space and jobs. Real estate firms such as CBRE rank clusters by their talent pools. Outside the US there is no single comparable ranking, so the European and Asian hubs below are described with the best available data for each.

Different rankings measure different things, so the order changes with the method. CBRE’s 2025 ranking of life-sciences R&D talent, for example, puts Boston/Cambridge first, the Bay Area second, Washington, D.C.–Baltimore third and New York–New Jersey fourth, followed by Los Angeles–Orange County, Raleigh–Durham, Philadelphia and San Diego. GEN’s ranking, which adds venture capital, NIH funding, patents and lab space, puts San Diego higher because of its strong venture funding. Read rankings as a guide to each hub’s strengths, not as a single league table.

The Leading US Biotech Hubs

GEN’s 2026 ranking, published in June 2026, kept the same top four as in recent years, with Greater Philadelphia making the biggest move into fifth place. The table shows the headline figures GEN reported for each of the top 10.

Boston/Cambridge is the reference point for every other hub. Kendall Square puts MIT, Harvard-affiliated hospitals, the R&D centers of many large pharma companies and hundreds of start-ups within walking distance, and the region has the most lab space in the country. CBRE’s 2025 talent report also ranked it first for life sciences R&D talent, a lead it widened in 2025.

The San Francisco Bay Area, the birthplace of the biotech industry, raised more venture capital than any other US cluster in 2025 and employs more people in biopharma than Boston. South San Francisco is its densest biotech district, and the overlap with Silicon Valley makes it the natural home for AI-driven drug discovery. We look at it in detail in our guide to AI drug discovery companies.

The BioHealth Capital Region around Washington, D.C., Maryland and Virginia benefits from proximity to the NIH and the FDA, while New York/New Jersey combines the highest NIH funding in the ranking with the headquarters of several large pharma companies. San Diego, built around the Torrey Pines research institutes, punches above its size in venture funding, and Greater Philadelphia has grown on the back of cell and gene therapy and new manufacturing investment.

Further down the list, each hub has a distinct profile. North Carolina, centered on Research Triangle Park, is one of the country’s main manufacturing bases, which matters more as companies move production back to the US. Los Angeles/Orange County has the largest life-sciences workforce in GEN’s ranking, at more than 155,000 jobs, much of it in medical devices and manufacturing, but attracted little biotech venture capital in 2025. Seattle is strong in protein design and immunotherapy research, while Chicagoland combines large hospital systems and universities with the headquarters of AbbVie and Abbott.

Europe’s Leading Hubs

The Golden Triangle (London, Oxford, Cambridge). Two of the world’s leading research universities, London’s capital markets and the R&D centers of AstraZeneca and GSK make this Europe’s most active biotech region. According to the UK BioIndustry Association, UK biotechs raised £1.9 billion in 2025, down from £3.7 billion in 2024, but the UK still accounted for about 30% of all European biotech venture financing. Large rounds for London-based Isomorphic Labs, the AI drug discovery company, made up a large share of the 2025 total.

Basel and the Swiss cluster. Basel is home to Roche and Novartis, and the wider Swiss cluster includes Lonza and a fast-growing start-up scene around Basel and Zurich. Basel Area Business & Innovation counts about 800 life-sciences companies in the Basel area, up from around 600 a decade ago. The region combines global headquarters, late-stage development and manufacturing, which makes it one of the world’s most important concentrations of pharma buying power.

Medicon Valley (Copenhagen and southern Sweden). Spanning Eastern Denmark and the Skåne region of Sweden, Medicon Valley is anchored by Novo Nordisk and has deep expertise in diabetes, obesity and metabolic disease. A regional analysis counted about 1,150 life-sciences companies and 65,500 employees in the cluster in 2022.

Munich, Paris-Saclay and the Leiden Bio Science Park in the Netherlands are the other important European centers. Munich’s cluster benefits from Germany’s large hospital and research system, Paris-Saclay concentrates French public research and start-ups south of Paris, and Leiden hosts one of Europe’s largest science parks next to its university medical center. European hubs tend to be smaller than their US peers and more dependent on public funding, which is one reason European biotechs often license assets to US and Asian partners earlier in development. Our biotech partnerships guide covers the deal structures European companies most often use.

Asia’s Leading Hubs

China: Shanghai, Suzhou, Beijing and the Greater Bay Area. China’s innovation is concentrated in four clusters. Shanghai’s Zhangjiang Pharma Valley is the base for multinational R&D centers and contract research and manufacturing; Suzhou’s BioBAY hosts more than 500 companies, and Suzhou Industrial Park has reported about 20% of China’s clinical approvals for Category 1 new drugs; Beijing combines academic institutions with proximity to the regulator; and the Guangzhou–Shenzhen–Hong Kong Greater Bay Area is strong in manufacturing and cell and gene therapy. Our China biotech clusters guide covers each in depth.

Hong Kong. Since 2018, HKEX Chapter 18A has allowed pre-revenue biotechs to list, making Hong Kong Asia’s main biotech capital market. By the end of January 2026, 84 companies had listed under Chapter 18A, raising more than US$17.5 billion, and listings recovered to 14 in 2025. Our Chapter 18A guide explains the rules.

Singapore. According to Singapore’s government, eight of the world’s ten largest biopharma companies run manufacturing facilities there, across more than 60 plants, and AstraZeneca is building a US$1.5 billion plant for antibody-drug conjugates. Singapore is also a common choice for Asia-Pacific regional headquarters.

Japan. Japan is the world’s fourth-largest pharmaceutical market, at about $64 billion in 2025 (IQVIA). Tokyo is home to Takeda, Astellas, Daiichi Sankyo and Chugai, and the Osaka–Kobe area to companies such as Shionogi. Japanese companies are active in-licensers of Western and Chinese assets, as our Japan market entry guide explains.

South Korea: Songdo. The Songdo district of Incheon is one of the world’s largest concentrations of biologics manufacturing. Samsung Biologics alone has 784,000 liters of bioreactor capacity, and Celltrion is based nearby.

Global Hubs at a Glance

The Forces Reshaping the Hub Map

Four forces are changing where biotech work happens and how hubs compete.

• Reshoring of manufacturing. GEN framed its 2026 ranking around companies bringing drug manufacturing back onto US soil, alongside mid-sized acquirers buying their own lab and manufacturing space and an improving climate for raising capital. Hubs with manufacturing land, workforce and incentives, such as North Carolina and Greater Philadelphia, benefit most.
• Supply-chain policy. The US BIOSECURE Act, signed in December 2025, is pushing companies that sell to US federal buyers to plan alternatives to designated Chinese providers, which supports manufacturing hubs in South Korea, Singapore, Europe and the US.
• Capital markets. Hong Kong’s Chapter 18A listings recovered in 2025, while the UK had no biotech IPOs for a third straight year and US venture capital remains concentrated in Boston and the Bay Area. Where companies can raise money shapes where they choose to grow.
• Incentives. Governments compete with tax breaks, lab space and grants. In China, for example, qualifying high- and new-technology enterprises pay a 15% corporate income tax rate instead of the standard 25%, and industrial parks add subsidies for regional headquarters and research facilities.

How the Hubs Connect Through Deals

The most important change in the hub map is not any single ranking. It is how tightly the hubs are now connected. Science discovered in Shanghai or Suzhou is licensed to pharma companies headquartered in Basel, New Jersey or Tokyo, developed with capital raised in Boston and the Bay Area, and manufactured in Songdo or Singapore.

China is the clearest example. Chinese out-licensing reached a record of roughly $136 billion in total deal value in 2025, according to our China Out-Licensing Report 2026, and GlobalData found that licensing deals in which US companies in-licensed an innovative drug from China reached almost 50% in 2025. Many of those assets are placed in NewCos funded by Boston and Bay Area investors, turning a Chinese molecule into a US-based company with Western investors and management.

Flows run the other way too. US and European biotechs license Greater China, Japanese or Korean rights to regional partners to raise non-dilutive capital, and Asian pharma companies are among the most active in-licensers at events such as JPM Week. Our 2027 conference calendar shows where those corridors meet in person.

Emerging Hubs to Watch

The established hubs face competition. In 2026 GEN published its first ranking of emerging US clusters, the Next 10, and placed Houston first, citing the most NIH funding among emerging regions (about $1.25 billion across 2,262 awards), around 28,000 jobs and about 8 million square feet of lab space. Minneapolis–St. Paul, Denver–Boulder and St. Louis were among the others recognized.

Elsewhere, regions are using universities, incentives and lower costs to compete for companies, from Madrid in Europe to Suzhou in China and Raleigh in North Carolina.

Choosing a Hub

• For founders: go where the specific talent and investors for your modality are. A platform company with AI at its core benefits from the Bay Area; a company built on a specific academic program usually stays near it.
• For investors: the established hubs offer deal flow and exits, while emerging hubs offer lower costs and less competition for the best companies.
• For pharma business development: scouting has to cover several hubs at once, because the most competitive assets in many classes now come from China as often as from Boston or San Diego.
• For Chinese companies going global: a US base in Boston, the Bay Area or San Diego brings access to talent, investors and FDA expertise. Our China biotech hub covers the cross-border options.
• For service providers and advisors: the hubs are where clients cluster, but the work increasingly happens between them. Being present in one hub and connected to the others is now the norm for firms that support cross-border deals.
• For Western companies entering Asia: Singapore and Hong Kong are common regional bases, with Shanghai and Tokyo for market access and partners.

The Bottom Line

Boston/Cambridge and the San Francisco Bay Area still lead the biotech world, followed by a strong group of US hubs, the Golden Triangle, Basel and Medicon Valley in Europe, and a fast-rising set of Asian hubs led by Shanghai and Suzhou. The more important trend is connection: science, capital and manufacturing now move between these hubs through licensing deals, NewCos and partnerships, and the companies that understand those corridors find the best assets and partners first.

If you are looking for partners, assets or investors in another hub, and want the introductions and the deal structure handled by people who work across these corridors every day, talk to our team.